Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE".
about
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE".
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Activity and safety of crizoti ...... phase 2 trial 90101 "CREATE".
@en
Activity and safety of crizoti ...... search and Treatment of Cancer
@nl
type
label
Activity and safety of crizoti ...... phase 2 trial 90101 "CREATE".
@en
Activity and safety of crizoti ...... search and Treatment of Cancer
@nl
prefLabel
Activity and safety of crizoti ...... phase 2 trial 90101 "CREATE".
@en
Activity and safety of crizoti ...... search and Treatment of Cancer
@nl
P2093
P50
P356
P1433
P1476
Activity and safety of crizoti ...... phase 2 trial 90101 "CREATE".
@en
P2093
A Anthoney
A Italiano
B Zakotnik
H Gelderblom
J Sufliarsky
L H Lindner
P304
P356
10.1093/ANNONC/MDX774
P577
2017-12-05T00:00:00Z